Starling Medical

Starling Medical develops daily at-home monitoring technology, including UrinDx, an at-home urine monitoring device that becomes part of a user's bathroom routine to track urinary health. The device sends health information nightly to Starling's care team, which reaches out with next steps if clinical concerns arise. Starling's program is reimbursed by insurance with most patients paying $0, and is currently pursuing FDA clearance. The platform targets recurrent urinary tract infection (rUTI) prevention through proactive care with a nurse-monitored dashboard and user-facing smartphone app, promoting good antibiotic stewardship and connecting patients to clinical care through partnerships with urology and primary care providers. Founded in 2020, headquartered in Houston, United States, The company has raised $13.1M at the Series A stage, backed by investors including America’s Seed Fund, Rebel Fund, Y Combinator, Innospark, Basis..